|
Market Closed -
NYSE
06:00:00 18/09/26 am AEST
|
5-day change | 1st Jan Change | ||
| 2.880 USD | +6.67% |
|
-3.68% | +4.73% |
| 19/08 | BMO Capital Initiates Perspective Therapeutics at Outperform | MT |
| 14/08 | BofA Securities Adjusts Perspective Therapeutics Price Target to $5 From $6 | MT |
Company Valuation: Perspective Therapeutics, Inc.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 55.03 | 35.12 | 112.8 | 215.6 | 204.4 | 308.2 | - | - |
| Change | - | -36.19% | 221.19% | 91.16% | -5.18% | 50.77% | - | - |
| Enterprise Value (EV) 1 | 55.03 | 35.12 | 112.8 | -8.207 | 61.26 | 141.7 | 77.35 | 145.7 |
| Change | - | -36.19% | 221.19% | -107.28% | 846.48% | 131.23% | -45.4% | 88.35% |
| P/E | -12.9x | -4.94x | -2.36x | -2.59x | -1.96x | -2.7x | -2.56x | -2.67x |
| PBR | - | - | - | 0.78x | 0.99x | 1.3x | 1.26x | 1.47x |
| PEG | - | -0.1x | -0x | 0.1x | -0.1x | 0.1x | -0.49x | 0.68x |
| Capitalization / Revenue | 5.47x | 9.89x | 78.7x | 148x | 231x | 963x | 778x | 333x |
| EV / Revenue | 5.47x | 9.89x | 78.7x | -5.64x | 69.3x | 443x | 195x | 158x |
| EV / EBITDA | -19.1x | - | - | 0.13x | -0.56x | -1.14x | -0.56x | -1.01x |
| EV / EBIT | -16x | - | -2.75x | 0.12x | -0.54x | -1.14x | -0.54x | -0.97x |
| EV / FCF | - | - | -2.97x | 0.11x | -0.64x | -1.27x | -0.54x | -0.96x |
| FCF Yield | - | - | -33.7% | 886% | -155% | -78.5% | -185% | -104% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -0.3 | -0.5 | -1.7 | -1.23 | -1.4 | -1.001 | -1.053 | -1.012 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 10.05 | 3.552 | 1.434 | 1.454 | 0.884 | 0.3201 | 0.3962 | 0.9246 |
| EBITDA 1 | -2.874 | - | - | -64.49 | -110.3 | -124.5 | -139 | -144.5 |
| EBIT 1 | -3.446 | - | -40.94 | -66.8 | -113.6 | -123.9 | -142.2 | -149.9 |
| Net income 1 | -3.39 | - | -46.51 | -79.28 | -103.1 | -114.8 | -135.2 | -142.2 |
| Net Debt 1 | - | - | - | -223.8 | -143.2 | -166.6 | -230.9 | -162.5 |
| Reference price 2 | 3.878 | 2.471 | 4.020 | 3.190 | 2.750 | 2.700 | 2.700 | 2.700 |
| Nbr of stocks (in thousands) | 14,192 | 14,211 | 28,057 | 67,588 | 74,338 | 114,152 | - | - |
| Announcement Date | 21/9/21 | 1/5/23 | 28/3/24 | 26/3/25 | 16/3/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (N) | EV / Sales (N) | EV / EBITDA (N) | Dividend Yield (N) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -2.7x | 442.58x | -1.14x | -.--% | 308M | |
| 31.46x | 5.67x | 16.98x | 1.03% | 45.91B | |
| 34.62x | 3.34x | 14.39x | -.--% | 44.25B | |
| -20.04x | 230.9x | -21.44x | -.--% | 41.99B | |
| 45.6x | 5.26x | 28.79x | -.--% | 39.58B | |
| 26.88x | 8.11x | 20.55x | 0.42% | 31.08B | |
| 35.05x | 5.75x | 26.13x | -.--% | 17.21B | |
| 24.9x | 2.15x | 9.33x | 1.07% | 14.96B | |
| 29.53x | 1.94x | 11.89x | -.--% | 13.42B | |
| Average | 22.81x | 78.41x | 11.72x | 0.28% | 27.63B | |
| Weighted average by Cap. | 24.71x | 43.66x | 12.23x | 0.31% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- CATX Stock
- Valuation Perspective Therapeutics, Inc.
Select your edition
All financial news and data tailored to specific country editions
